Peptidomimetic design

Current Opinion in Chemical Biology

Volumn 2, Issue 4, 1998, Pages 441-452

  Ripka, Amy S ^a   Rich, Daniel H ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE; ENZYME INHIBITOR; PEPTIDE;

CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; FORECASTING; MOLECULAR MIMICRY; PROTEIN CONFORMATION; REVIEW;

ASPARTIC ENDOPEPTIDASES; DRUG DESIGN; ENZYME INHIBITORS; FORECASTING; MOLECULAR MIMICRY; PEPTIDES; PROTEIN CONFORMATION;

EID: 0032133429     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(98)80119-1     Document Type: Article

References (65)

1. Babine RE, Bender SL: Molecular recognition of protein-ligand complexes: applications to drug design. Chem Rev 1997, 97:1359-1472. This paper provides an outstanding compilation of X-ray structures used to design enzyme inhibitors.
2. Lam KS, Lebl M, Krchnák V: The One-bead-one-compound' combinatorial library method. Chem Rev 1997, 97:411-448. A current summary of recent developments in computer software and strategies for de novo design of enzyme inhibitors.
3. Bohacek RS, McMartin C: Modern computational chemistry and drug discovery: structure generating programs. Curr Opin Chem Biol 1997, 1:157-161.
4. Szelke M, Leckie B, Hallett A, Jones DM, Sueiras J, Atrash B, Lever AF: Potent new inhibitors of human renin. Nature 1982, 299:555-557.
5. Wiley RA, Rich DH: Peptidomimetics derived from natural products. Med Res Rev 1993, 13:327-384.
6. Sautel M, Rudolf K, Wittneben H, Herzog H, Martinez R, Munoz M, Eberlein W, Engel W, Walker P, Beck-Sickinger AG: Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor. Mol Pharmacol 1996, 50:285-292.
7. Schwartz TW: Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 1994, 5:434-444.
8. Fairlie DP, Abbenante G, March DR: Macrocyclic peptidomimetics - forcing peptides into bioactive conformations. Curr Med Chem 1995, 2:654-686.
9. Liskamp RMJ: Conformationally restricted amino acids and dipeptide, (non)peptidomimetics and secondary structure mimetics. Rec Trav Chim - J R Meth Chem Soc 1994, 113:1-19.
10. Hanessian S, McNaughton-Smith G, Lombart H-G, Lubell WD: Design and synthesis of conformationally constrained amino acids as versatile scaffolds and peptide mimetics. Tetrahedron 1997, 53:12789-12854.
11. Giannis A, Kolter T: Peptidomimetics for receptor ligands - discovery, development, and medical perspectives. Angew Chem Int Ed Engl 1993, 32:1244-1267.
12. Gante J: Peptidomimetics - tailored enzyme inhibitors. Angew Chem Int Ed Engl 1994, 33:1699-1720.
13. Yamashita DS, Smoth WW, Zhao B, Janson CA, Tomaszek TA, Bossard MJ, Levy MA, Oh H-J, Carr TJ, McQueney M et al.: Structure and design of potent and selective cathepsin K inhibitors. J Am Chem Soc 1997, 119:11351-11352. This paper provides an example of enzyme-inhibitor crystal structure data leading to the fusion of primed and unprimed inhibitors to produce a selective inhibitor spanning the entire active site of the enzyme.
14. Thompson SK, Halbert SM, Bossard MJ, Tomaszek TA, Levy MA, Zhao B, Smith WA, Abdel-Meguid SS, Janson CA, D-Alessio KJ et al.: Design of potent and selective human cathepsin K inhibitors that span the active site. Proc Natl Acad Sci USA 1997, 94:14249-14254.
15. McGrath ME, Klaus JL, Barnes MG, Brömme D: Crystal structure of human cathepsin k complexed with a potent inhibitor. Nat Struct Biol 1997, 4:105-108.
16. 1)-moieties. A novel strategy towards small non-peptide renin inhibitors. Bioorg Med Chem Lett 1996, 6:1589-1594.
17. Göschke R, Cohen NC, Wood JM, Maibaum J: Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin. Bioorg Med Chem Lett 1997, 7:2735-2740. The authors describe a novel approach to the unusual type-I renin inhibitor.
18. 1′ sites. Bioorg Med Chem Lett 1993, 3:2119-2124.
19. 3 peptidomimetic class of interleukin-1β-converting enzyme inhibitor. J Med Chem 1997, 40:1941-1946.
20. Golec JMC, Mullican MD, Murcko MA, Wilson KP, Kay DP, Jones SD, Murdoch R, Bemis GW, Raybuck SA, Luong Y-P, Livingston DJ: Structure-based design of non-peptidic pyridone aldehydes as inhibitors of interleukin-1β converting enzyme. Bioorg Med Chem Lett 1997, 7:2181-2186.
21. Dolle RE, Prouty CP, Prasad CVC, Cook E, Saha A, Ross TM, Salvino JM, Helaszek CT, Ator MA: First examples of peptidomimetic inhibitors of interleukin-1β converting enzyme. J Med Chem 1996, 39:2438-2440.
22. McKittrick BA, Stamford AW, Weng X, Ma K, Chackalamannil S, Czarniecki M, Cleven RM, Fawzi AB: Design and synthesis of phosphonic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11. Bioorg Med Chem Lett 1996, 6:1629-1634.
23. De Lombaert S, Chatelain RE, Fink CA, Trapani AJ: Design and pharmacology of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors. Curr Pharm Des 1996, 2:443-462.
24. De Lombaert S, Stamford LB, Blanchard L, Tan J, Hoyer D, Diefenbacher CG, Wei D, Wallace EM, Moskal MA, Savage P, Jeng AY: Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase. Bioorg Med Chem Lett 1997, 7:1059-1064.
25. Ksander GM, de Jesus R, Yuan A, Ghai RD, McMartin C, Bohacek R: Meta-substituted benzofused macrocyclic lactams as zinc metalloprotease inhibitors. J Med Chem 1997, 40:506-514.
26. Brown DL, Devadas B, Lu H-F, Nagarajan S, Zupec ME, Freeman SK, McWherter CA, Getman DP, Sikorski JA: Replacements for lysine in L-seryl-L-lysyl dipeptide amide inhibitors of Candida albicans myristoyl-CoA: protein N-myristoyltransferase. Bioorg Med Chem Lett 1997, 7:379-382.
27. Moss N, Beaulieu P, Duceppe J-S, Ferland J-M, Gauthier J, Ghiro E, Goulet S, Guse I, Llinês-Brunet M, Plante R et al.: Ureido-based peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase: an investigation of inhibitor bioactive conformation. J Med Chem 1996, 39:2178-2187. An interesting example of small, type-I peptidomimetic that can inhibit protein-protein interactions.
28. Moss N, Beaulieu P, Duceppe J-S, Ferland J-M, Garneau M, Gauthier J, Ghiro E, Goulet S, Guse I, Jaramillo J et al.: Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity. J Med Chem 1996, 39:4173-4180.
29. Xue C-B, Roderick J, Jackson S, Rafalski M, Rockwell A, Mousa S, Olson RE, DeGrado WF: Design, synthesis and in vitro activities of benzamide-core glycoprotein IIb/IIIa antagonists: 2,3-diaminoproprionic acid derivatives as surrogates of aspartic acid. Bioorg Med Chem 1997, 5:693-705.
30. Fisher MJ, Gunn B, Harms CS, Kline AD, Mullaney JT, Nunes A, Scarborough RM, Arfsten AE, Skelton MA, Um SL et al.: Non-peptide RGD surrogates which mimic a Gly-Asp β-turn: potent antagonists of platelet glycoprotein IIb-IIIa. J Med Chem 1997, 40:2085-2101.
31. Blackburn BK, Lee A, Baier M, Kohl B, Olivero AG, Matamoros R, Robarge KD, McDowell RS: From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1h-1,4-benzodiazepine-2,5-dione nucleus. J Med Chem 1997, 40:717-729.
32. Liverton NJ, Armstrong DJ, Claremon DA, Remy DC, Baldwin JJ, Lynch RJ, Zhang G, Gould RJ: Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists. Bioorg Med Chem Lett 1998, 8:483-486.
33. Prugh JD, Gould RJ, Lynch RJ, Zhang G, Cook JJ, Holahan MA, Stranieri MT, Sitko GR, Gaul SL, Bednar RA et al.: Nonpeptide GPIIb/IIIa inhibitors. 16. Thieno[2,3-b]thiophene α-sulfonamides are potent inhibitors of platelet aggregation. Bioorg Med Chem Lett 1997, 7:865-870.
34. Askew BC, McIntyre CJ, Hunt CA, Claremon DA, Baldwin JJ, Anderson PS, Gould RJ, Lynch RJ, Chang CC-T, Cook JJ et al: Nonpeptide glycoprotein IIb/IIIa inhibitors. 13. Design and synthesis of an orally active pyrazolopiperazinone nonpeptide fibrinogen recepor antagonist. Bioorg Med Chem Lett 1997, 7:1531-1536.
35. Ripka WC, Vlasuk GP: Antithrombotics/Serine Proteases. In Annual Reports in Medicinal Chemistry. Edited by Doherty AM. New York: Academic Press; 1997:71-89.
36. Quan ML, Pruitt JR, Ellis CD, Liauw AY, Galemmo RA, Stouten PFW, Wityak J, Knabb RM, Thoolen MJ, Wong PC, Wexler RR: Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett 1997, 7:2813-2818.
37. Maduskuie TP, McNamara KJ, Ru Y, Knabb RM, Stouten PFW: Rational design and synthesis of novel, potent bisphenylamidine carboxylate factor Xa inhibitors. J Med Chem 1998, 41:53-62.
38. Nagahara T, Yokoyama Y, Inamura K, Katakura S, Komoriya S, Yamaguchi H, Hara T, Iwamoto M: Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J Med Chem 1994, 37:1200-1207.
39. Brandstetter H, KYhne A, Bode W, Huber R, von der Saal W, Wirthensohn K, Engh RA: X-ray structure of active site-inhibited clotting factor Xa. J Biol Chem 1996, 271:29988-29992.
40. Klein SI, Czekaj M, Gardner CJ, Guertin KR, Cheney DL, Spada AP, Bolton SA, Brown K, Colussi D, Heran CL et al.: Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa. J Med Chem 1998, 41:437-450.
41. Buckman BO, Mohan R, Liang A, Trinh L, Morrissey MM: Design, synthesis and biological activity of novel factor Xa inhibitors. 6. Bicyclic pyrimidine analogues of 2,6-diphenoxypyridine inhibitors. Book of Abstracts. 215th American Chemical Society National Meeting: 1998 March 29-April 2; Dallas. Washington, DC: American Chemical Society: 1998, A126.
42. Wiley MR, Chirgadze NY, Clawson DK, Craft TJ, Gifford-Moore DS, Jones ND, Olkowski JL, Schacht AL, Weir LC, Smith GF: Serine protease selectivity of the thrombin inhibitor D-Phe-Pro-Agmatine and its homologs. Bioorg Med Chem Lett 1995, 5:2835-2840.
43. Brady SF, Stauffer KJ, Lumma WC, Smith GM, Ramjit HG, Lewis SD, Lucas BJ, Gardell SJ, Lyle EA, Appleby SD et al.: Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyltrans-4-aminocyclohex ylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support. J Med Chem 1998, 41:401-406.
44. Tucker TJ, Lumma WC, Mulichak AM, Chen Z, Naylor-Olsen AM, Lewis SD, Lucas R, Freidinger RM, Kuo LC: Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J Med Chem 1997, 40:830-832. This paper presents a major new approach for designing protease inhibitors.
45. Tucker TJ, Lumma WC, Mulichk AM, Chen Z, Naylor-Olsen AM, Lewis SD, Lucas R, Freidinger RM, Kuo LC: Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J Med Chem 1997, 40:830-832.
46. Sall DJ, Bastian JA, Briggs SL, Buben JA, Chirgadze NY, Clawson DK, Denney ML, Gierra DD, Gifford-Moore DS, Harper RW et al.: Dibasic benzo[b]thiophene derivatives as a novel class of thrombin inhibitors. 2. In vitro thrombin inhibition as a function of conformational effects and lipophilicity in the C-4′ sidechain. Book of Abstracts. 214th American Chemical Society National Meeting: 1997 Sept 7-11: Las Vegas. Washington, DC: American Chemical Society; 1997:A58.
47. Chirgadze NY, Sall DJ, Klimkowski VJ, Clawson DK, Briggs SL, Hermann R, Smith GF, Gifford-Moore DS, Wery J-P: The crystal structure of human α-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitor. Protein Sci 1997, 6:1412-1417.
48. Geratz JD, Stevens FM, Polakoski KL, Parrish RF, Tidwell RR: Amidino-substituted aromatic heterocycles as probes of the specificity pocket of trypsin-like proteases. Arch Biochem Biophys 1979, 197:551-559.
49. Malley MF, Tabernero L, Chang CY, Ohringer SL, Roberts DGM, Das J, Sack JS: Crystallographic determination of the structures of human α-thrombin complexed with BMS-186282 and BMS-189090. Protein Sci 1996, 5:221-228.
50. Wessel HP, Banner D, Gubernator K, Hilpert K, MYller K, Tschopp T: 6-Guanidinopyranoses: novel carbohydrate based peptidomimetics. Angew Chem Int Ed Engl 1997, 36:751-752.
51. Hilpert K, Ackermann J, Banner DW, Gast A, Gubernator K, Hadváry P, Labler L, Müller K, Schmid G, Tschopp TB, van de Waterbeemd H: Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem 1994, 37:3889-3901.
52. Obst U, Banner DW, Weber L, Diederich F: Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes. Chem Biol 1997, 4:287-295.
53. Beaulieu PL, Lavallée P, Abraham A, Anderson PC, Boucher C, Bousquet Y, Duceppe J-S, Gillard J, Gorys V, Grand-Matre C et al.: Practical, stereoselective synthesis of Palinavir, a potent HIV protease inhibitor. J Org Chem 1997, 62:3440-3448.
54. Kim EE, Baker CT, Dwyer MD, Murcko MA, Rao BG, Tung RD, Navia MA: Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc 1995, 117:1181-1182.
55. Kaldor SW, Kalish VJ, Davies JF, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK et al.: Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 1997, 40:3979-3985. This is the first description of an important second generation anti-HIV protease inhibitor.
56. Hagen SE, Vara Prasad JVN, Boyer FE, Domagala JM, Ellsworth EL, Gajda C, Hamilton HW, Markoski LJ, Steinbaugh BA, Tait BD et al.: Synthesis of 5,6-dihydro-4-hydroxy-2-pyrones as HIV-1 protease inhibitors: the profound effect of polarity on antiviral activity. J Med Chem 1997, 40:3707-3711. This paper provides an excellent overview of the research that led to the discovery of an important HIV protease inhibitor.
57. Judge TM, Phillips G, Morris JK, Lovasz KD, Romines KR, Luke GP, Tulinsky J, Tustin JM, Chrusciel RA, Dolak LA et al.: Asymmetric syntheses and absolute stereochemistry of 5,6-dihydro-α-pyones, a new class of potent HIV protease inhibitors. J Am Chem Soc 1997, 119:3627-3628. A landmark paper, which describes the discovery of an orally active, type-III HIV protease inhibitor by rationale drug design applied to screening leads.
58. De Lucca GV, Erickson-Viitanen S, Lam PYS: Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule. Drug Discov Today 1997, 2:6-18.
59. Leonard DM: Ras farnesyltransferase: a new therapeutic target J Med Chem 1997, 40:2971-2990. An outstanding example of structure-based drug design of a Type-III HIV protease inhibitor.
60. Qian Y, Sebti SM, Hamilton AD: Farnesyltransferase as a target for anticancer drug design. Biopolymers 1997, 43:25-41.
61. Hunt JT, Lee VG, Leftheris K, Seizinger B, Carboni J, Mabus J, Ricca C, Yan N, Manne V: Potent, cell active, non-thiol tetrapeptide inhibitors of farnesyltransferase. J Med Chem 1996, 39:353-358.
62. Njoroge FG, Doll RJ, Vibulbhan B, Alvarez CS, Bishop WR, Petrin J, Kirschmeier P, Carruthers NI, Wong JK, Albanese MM et al: Discovery of novel nonpeptide tricyclic inhibitors of ras farnesyl protein transferase. Bioorg Med Chem 1997, 5:101-113.
63. Bishop WR, Bond R, Petrin J, Wang L, Patton R, Doll R, Njoroge G, Catino J, Schwartz J, Windsor W et al.: Novel tricyclic inhibitors of farnesyl protein transferase. J Biol Chem 1995, 270:30611-30618.
64. Rich DH, Bohacek RS, Dales NA, Glunz P, Ripka AS: Transformation of peptides into non-peptides. Synthesis of computer generated enzyme inhibitors. Chimia 1997, 51:45-47.
65. Bottomley KM, Johnson WH, Walter DS: Matrix metalloproteinase inhibitors in arthritis. J Enz Inhib 1998, 13:79-101. This is an excellent review of research leading to a matrix metalloprotease inhibitor that is now in developnent.